Premier Alternatives

Aviceda Therapeutics

Cambridge, MA · Founded 2018 · Privately Held (backing)

Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients. Aviceda Therapeutics is based in Cambridge, MA and was founded in 2018. It was valued at $347 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $276 million across 3 recorded rounds; the latest was a $75 million later-stage round in Nov 2024.

PMV mark · valuation
$346.5M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$276.3M
Last round
Later Stage VC
Nov 2024

Aviceda Therapeutics key facts

as of Oct 2026
  • Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients.
  • Aviceda Therapeutics is valued at approximately $346.5M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $276.3M across 3 recorded rounds; the latest was Later Stage VC ($75.0M) in Nov 2024.
  • Notable investors include OrbiMed, Catalio Capital Management, Blue Owl Capital, Digitalis Ventures, Logos Capital — 13 tracked in total.
  • Aviceda Therapeutics has filed 4 Form Ds with the SEC since 2023, most recently Jan 2025 ($75.0M sold to 17 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$346.5M

Valued at $346.5M at its later-stage round, Jan 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Aviceda Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Aviceda Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Aviceda Therapeutics funding rounds

3 rounds
Nov 2024Later Stage VC$75.0MSEC filing▮
May 2024Early Stage VC$18.9MSEC filing▮
May 2023Early Stage VC$15.6MSEC filing▮
Full funding history →

Aviceda Therapeutics valuation

Aviceda Therapeutics was valued at $347 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Aviceda Therapeutics raised?

Aviceda Therapeutics has raised $276 million in total; 3 of its rounds are on record, from 2023 on. The largest on record was a $75 million later-stage round in Nov 2024.

Aviceda Therapeutics has filed 4 Form Ds with the SEC since 2023, most recently in Jan 2025 ($75 million sold to 17 investors).

Aviceda Therapeutics investors

13 investors are on record for Aviceda Therapeutics, including OrbiMed, Catalio Capital Management, Blue Owl Capital and Digitalis Ventures. By type, the record holds 3 venture capital firms, 2 hedge funds and 1 private equity firm. The later-stage round in Nov 2024 drew 17 investors.

About Aviceda Therapeutics

Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients. The company combines biology with a cell-based screening platform and proprietary nanoparticle technology to modulate the innate immune response and lead to ophthalmic-optimized nanoparticles, enabling medical researchers to address chronic non-resolving inflammation in patients.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2018
Employees
33
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.